Skip to main content
Premium Trial:

Request an Annual Quote

America's Choice Provider Network to Cover CombiMatrix's Molecular Dx Testing Services

NEW YORK (GenomeWeb News) – America's Choice Provider Network will now cover CombiMatrix's diagnostic laboratory services, CombiMatrix said today.

ACPN is a San Diego-based company that facilitates out-of-network services for more than 540 payers in the US, reaching about 14 million people. Under the new agreement, individuals whose healthcare providers liaise with ACPN will now have access to CombiMatrix's menu of chromosomal microarray-based prenatal, pediatric, and cancer cytogenetic testing services.

In addition to CMA, Irvine, Calif.-based CombiMatrix also offers fluorescence in situ hybridization, PCR and G-band chromosome analyses.

The firm, which saw its third quarter revenues rise 15 percent on increased prenatal testing volumes, has announced a number of payor agreements this year. Earlier this month, it announced a deal with Blue Cross and Blue Shield of Kansas City. In October, CombiMatrix said it had reached a deal with Three Rivers Provider Network, and during the summer it inked an agreement with Blue Shield of California.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.